Abstract
Recently, image-based diagnostic technology has made encouraging and astonishing development. Modern medical care and imaging technology are increasingly inseparable. However, the current diagnosis pattern of Signal-to-Image-to-Knowledge inevitably leads to information distortion and noise introduction in the procedure of image reconstruction (Signal-to-Image). Artificial intelligence (AI) technologies that can mine knowledge from vast amounts of data offer opportunities to disrupt established workflows. In this prospective study, for the first time, we developed an AI-based Signal-to-Knowledge diagnostic scheme for lung nodule classification directly from the CT rawdata (the signal). We found that the rawdata achieved almost comparable performance with CT indicating that we can diagnose diseases without reconstructing images. Meanwhile, the introduction of rawdata could greatly promote the performance of CT, demonstrating that rawdata contains some diagnostic information that CT does not have. Our results break new ground and demonstrate the potential for direct Signal-to-Knowledge domain analysis.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Protocols
https://clinicaltrials.gov/ct2/show/NCT04241614
Funding Statement
This work was supported by the National Key R&D Program of China (2017YFA0205200), National Natural Science Foundation of China (82022036, 91959130, 81971776, 62027901, 81930053, 81771924), the Beijing Natural Science Foundation (Z20J00105), Strategic Priority Research Program of Chinese Academy of Sciences (XDB38040200), Chinese Academy of Sciences under Grant No. GJJSTD20170004 and QYZDJ-SSW-JSC005, the Project of High-Level Talents Team Introduction in Zhuhai City (Zhuhai HLHPTP201703), the Youth Innovation Promotion Association CAS (Y2021049) and the China Postdoctoral Science Foundation (2021M700341).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The methods were performed in accordance with Standards for Reporting Diagnostic accuracy studies (STARD) and approved by the Ethics Committee of the First Hospital of Jilin University (AF-IRB-032-05).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The image features and output values associated with the CTMs and the RGMs are stored on GitHub (https://github.com/CASIAMI/rawdata_gain). The original data that support the findings of this study are available from the corresponding author upon reasonable request.
